scispace - formally typeset
D

David Spaner

Researcher at Sunnybrook Health Sciences Centre

Publications -  69
Citations -  4100

David Spaner is an academic researcher from Sunnybrook Health Sciences Centre. The author has contributed to research in topics: Chronic lymphocytic leukemia & Antigen. The author has an hindex of 22, co-authored 66 publications receiving 3724 citations. Previous affiliations of David Spaner include Women's College, Kolkata & University of Toronto.

Papers
More filters
Journal ArticleDOI

B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor–transduced T cells

TL;DR: Pro adoptive transfer of T cells genetically modified to express an anti-CD19 chimeric Ag receptor (CAR) has great promise to improve the treatment of B-cell malignancies because of a potent ability to eradicate CD19(+) cells in vivo; however, reversible cytokine-associated toxicities occurred after CAR-transduced T-cell infusions.
Journal ArticleDOI

Intensive chemotherapy and autologous stem-cell transplantation plus rituximab is superior to conventional chemotherapy for newly diagnosed advanced stage mantle-cell lymphoma: a matched pair analysis

TL;DR: This matched-pair analysis suggests that patients with advanced-stage MCL treated with ASCT-rituximab had statistically significantly better PFS and a trend toward better OS than patients treated with conventional chemotherapy.
Journal ArticleDOI

Comprehensive Lipidomics Analysis of Bioactive Lipids in Complex Regulatory Networks

TL;DR: The method allowed us to examine eicosanoid profiles within the signaling cascade in chronic lymphocytic leukemia (CLL) cells under basal conditions and following arachidonic acid stimulation, and demonstrated that the performance of the assay was very similar to that of a quadrupole linear ion trap assay.
Journal Article

Chronic Lymphocytic Leukemia-reactive T Cells during Disease Progression and after Autologous Tumor Cell Vaccines

TL;DR: Tumor-reactive T cells exist in some CLL patients and may potentially mediate therapeutic responses if their numbers and activation states can be sufficiently increased by tumor vaccines.